UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a virtual fireside chat at the TD Cowen 5th.
UroGen Pharma (NASDAQ:URGN – Free Report) had its price target cut by Oppenheimer from $34.00 to $32.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have an outperform rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $54.00 target price on shares of UroGen Pharma […]
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call Transcript insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
North American Morning Briefing : Stock Futures -2- marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.